ASCO 2024 | Combining durvalumab & BVAC-C to enhance anti-tumor immune responses in recurrent cervical carcinoma
Chel Hun Choi, MD, Samsung Medical Center, Seoul, South Korea, discusses the combination of durvalumab and BVAC-C in addressing the limitations of single-agent immunotherapies in patients with recurrent cervical carcinoma. Immune checkpoint inhibitors’ effectiveness largely depends on PD-L1 and PD-1 expression. However, these immune-suppressive molecules can undermine the anti-tumor response to HPV oncoprotein-targeting immunotherapy like BVAC-C. The combination aims to enhance the anti-tumor response by targeting both the immune checkpoint inhibitor pathway and HPV oncoproteins. The Phase I/IIa study (NCT04800978) aims to evaluates the efficacy of BVAC-C with durvalumab in patients with recurrent cervical carcinoma regardless of PD-L1 status, potentially enhancing the anti-tumor response in a broader patient population. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
